Atypical mycobacteriosis treatment market seen reaching $3.17 billion by 2030
The atypical mycobacteriosis treatment market is forecast to grow from $2.54 billion in 2026 to $3.17 billion by 2030, as diagnostics improve and demand rises for personalized care. North America held the largest share in 2025, while the report points to growing use of combination therapies, longer treatment courses and outpatient care.
Why it matters: - The market is expanding as nontuberculous mycobacterial infections become more visible and treatment options broaden. - Growth in this niche market reflects rising demand for longer, more specialized care for lung, skin and lymph node infections that often resist standard tuberculosis drugs. - The forecast points to more spending on diagnostics, antibiotics and supportive care for patients with complex respiratory disease.
What happened: - The Business Research Company published its Atypical Mycobacteriosis Treatment Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report estimates the market will rise from $2.4 billion in 2025 to $2.54 billion in 2026, a 5.9% compound annual growth rate. - The market is projected to reach $3.17 billion by 2030, growing at a 5.7% CAGR. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - More information is available in the company's announcement.
The details: - Historical growth has been supported by better clinical diagnosis of nontuberculous mycobacterial infections. - Wider availability of macrolide-based therapies helped expand treatment access. - Specialized infectious disease care and higher hospital adoption supported the market. - Improved methods to distinguish NTM infections from tuberculosis also aided growth. - Expected growth drivers include a larger immunocompromised population. - Research into new antimycobacterial drugs is expected to accelerate. - Personalized treatment approaches are becoming more common. - Outpatient and home healthcare services are expanding. - Clinical guidelines for managing NTM are becoming more refined. - Expected trends include more combination antibiotic therapy. - Drug-resistant NTM strains are drawing more attention. - Prolonged treatment regimens are likely to become more common. - Targeted surgical procedures and supportive care are also expected to grow. - Atypical mycobacteriosis treatment usually combines antibiotics such as macrolides, rifamycins and ethambutol over extended periods.
Between the lines: - Personalized medicine is a major tailwind because treatment can be tailored to genetic, biological and environmental characteristics. - The report cites the Personalized Medicine Coalition saying the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - COPD trends also support demand because NTM infections can worsen respiratory symptoms and speed disease progression. - The report cites Australia’s Institute of Health and Welfare saying COPD accounted for 3.6% of the total disease burden in Australia in 2023 and half of all respiratory-related disease burden. - That was up from 2.5% in 2022, a 44% year-over-year increase.
What's next: - The market outlook points to continued growth through 2030 as more patients are diagnosed and treated earlier. - The report expects more use of outpatient care, home-based treatment and individualized regimens. - The report also added new tools in the 2026 edition, including TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.
The bottom line: - Atypical mycobacteriosis treatment is moving from a specialized niche toward a larger, more structured market, with personalized care and better diagnostics shaping the next phase of growth.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
News Central Australia
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.